Please login to the form below

Not currently logged in
Email:
Password:

PD-L1 inhibitor

This page shows the latest PD-L1 inhibitor news and features for those working in and with pharma, biotech and healthcare.

More good news, and some bad, for Merck’s Keytruda

More good news, and some bad, for Merck’s Keytruda

It’s the second priority review filing for Keytruda to get underway at the FDA in a week, coming after the PD-1 inhibitor was filed as a first-line treatment ... The rare setback for Keytruda comes as it has started to show signs of lengthening its new

Latest news

  • Cancer drugs and China sustain AZ’s return to growth Cancer drugs and China sustain AZ’s return to growth

    Lynparza (olaparib) for ovarian and breast cancer saw sales more than double to $647m, while PD-L1 inhibitor Imfinzi rocketed to $633m from just $19m in 2017 following its approval for ... BTK inhibitor Calquence (acalabrutinib) – a rival to

  • BMS isn’t phased by Opdivo’s slowing growth – for now BMS isn’t phased by Opdivo’s slowing growth – for now

    Merck took a narrower approach with Keytruda, hitting the mark in a trial in patents with high PD-L1 expression which got its toe into the first-line market, and then ... programme as the PD-1/PD-L1 inhibitor market gets ever more competitive with six

  • Advaxis shaken by another FDA hold on cervical cancer vaccine Advaxis shaken by another FDA hold on cervical cancer vaccine

    One of those trials involved a combination of Axal with AstraZeneca’s PD-L1 inhibitor Imfinzi for advanced, recurrent or refractory cervical cancer and HPV-associated head and neck cancer.

  • EU approval for Opdivo combo in renal cell cancer EU approval for Opdivo combo in renal cell cancer

    a 37% decreased risk of death in intermediate- and poor-risk patients compared to a Sutent, observed regardless of PD-L1 expression level. ... category with its IMmotion 151 study comparing PD-L1 inhibitor Tecentriq plus Avastin to Sutent, which

  • Chinese biotechs aim PD-L1 antibody at hepatitis B Chinese biotechs aim PD-L1 antibody at hepatitis B

    Suzhou Alphamab is already testing its PD-L1 inhibitor antibody KN035 in a number of clinical trials across tumour types in the US, China and Japan, but has licensed rights for ... Blocking the PD-1/PD-L1 pathway could be an effective immunotherapy

More from news
Approximately 4 fully matching, plus 114 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies. ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast.

  • Pharma deals during November 2014 Pharma deals during November 2014

    AZ has been busy this month and in the deal with J&J, AZ will match its closely-watched PD-L1 checkpoint inhibitor MEDI4736 with Imbruvica. ... This deal gives Pfizer co-development and co-marketing rights to MSB0010718C, Merck KGaA's anti-PD-L1

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics